Welcome to PRI

Founded in 2002, the Pharmaceutical Research Institute (PRI) at Albany College of Pharmacy and Health Sciences is a center for drug discovery and development.

PRI investigators possess expertise in fields that include nanotechnology, medicinal chemistry, molecular biology, and cell biology.

Areas of focus include: hematology/oncology, cardiovascular (dyslipidemia), ophthalmology, vascular diseases, neurology, and inflammation.

As part of its mission, PRI is also engaged in teaching and learning. Pharmacy students, graduate students, and visiting scholars from around the world visit the Institute to conduct research and learn the latest advances across a wide range of therapeutic areas.

Recent Publications

  • Modulation of Sickle Red Blood Cell Adhesion and its Associated Changes in Biomarkers by Sulfated Nonanticoagulant Heparin Derivative

    This study compares the inhibitory effect of a sulfated non-anticoagulant heparin (S-NACH) derivative with a low molecular weight heparin, tinzaparin, on the adhesion of sickle RBCs to endothelium. S-NACH exhibits minimum effects on hemostasis and bleeding and interferes with the binding of pancreatic cancer cells to endothelial cells via P-selectin.

    Read more
  • Oral Administration of Naturally Occurring Chitosan-Based Nanoformulated Green Tea Polyphenol Egcg Effectively Inhibits Prostate Cancer Cell Growth in a Xenograft Model

    In preclinical animal models, several phytochemicals have shown excellent potential to be used as effective agents in preventing and treating many cancers. However, the limited bioavailability of active agents could be one reason for their restricted usefulness for human consumption.

    Read more